ArticleThoracic cancer2025
Surgical Expert Consensus on Clinical Management of Advanced Thymoma and Thymic Carcinoma: A Beijing-Tianjin-Hebei Collaborative Initiative.
Article in Thoracic cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Advanced thymic epithelial tumours after neoadjuvant therapy: a narrative review of surgical challenges and strategies.Mediastinum (Hong Kong, China) · 2026Review
- Optimising individualised treatment decisions for locally advanced thymoma: precision selection of minimally invasive surgery and postoperative adjuvant radiotherapy.Frontiers in oncology · 2026Review
- Neoadjuvant Glucocorticoids Facilitate Resection in Advanced B-Type Thymomas: A Propensity-Matched Analysis of Surgical and Survival Outcomes.Thoracic cancer · 2026Article
- Management of liver metastases secondary to thymic epithelial tumors: a narrative review of current management and future directions.Mediastinum (Hong Kong, China) · 2026Review
- Surgical Expert Consensus on Clinical Management of Advanced Thymoma and Thymic Carcinoma: A Beijing-Tianjin-Hebei Collaborative Initiative.Thoracic cancer · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Thymomas and thymic carcinomas represent rare epithelial-derived thoracic neoplasms that, despite their low incidence, pose significant clinical challenges and impact patient survival. Through collaborative efforts among experts across the Beijing-Tianjin-Hebei region, this consensus seeks to provide guidance for the challenging management of advanced-stage thymic epithelial tumors (Stages IIb-IV). Advanced thymic tumors frequently present with local invasion or distant metastases, necessitating multimodal therapeutic approaches incorporating surgery, radiotherapy, chemotherapy, and emerging immunotherapies. Treatment individualization remains paramount given tumor heterogeneity and variable clinical presentations. This regional consensus framework endeavors to offer evidence-based guidance for thymic tumor management, promoting coordinated care through multidisciplinary teams that may help improve therapeutic outcomes and patient survival. Through collaborative efforts, we hope to foster greater consistency in treatment approaches across participating institutions, potentially contributing to enhanced regional oncological care via the careful integration of contemporary therapeutic strategies for patients with advanced thymic epithelial neoplasms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.